EGFR and non-small cell lung carcinoma: Interestingly, high levels of miR-762 predisposed the NSCLC patients receiving EGFR-TKIs chemotherapy to a significantly shorter progression-free survival (Fig. 6c) and overall survival time (Fig. 6d).